Where to Buy Mounjaro (Tirzepatide): Research Supply Guide
Tirzepatide Research
GIP / GLP-1 Research
Last Updated: May 2026
Prescription-Only Medicine — Important Notice
Mounjaro (tirzepatide) is a prescription-only medication in many jurisdictions including the UK. It cannot be legally obtained without a valid prescription from a licensed prescriber. Pure Grade Labs does not sell Mounjaro. Pure Grade Labs supplies research-grade tirzepatide strictly for laboratory research purposes only. Not for human consumption.
If you are searching to buy Mounjaro, there is a distinction you need to understand before proceeding: Mounjaro is a branded prescription drug manufactured by Eli Lilly, available only via a licensed prescriber in the UK — it is not sold over the counter and it is not available from research chemical suppliers. What researchers in the UK can legitimately source is research-grade tirzepatide — the same active molecule as Mounjaro, but supplied as a laboratory research chemical under an entirely different regulatory framework. This guide explains the distinction clearly: what Mounjaro is, why it requires a prescription, what research-grade tirzepatide is, and how Pure Grade Labs supplies tirzepatide for legitimate scientific research. If you are a researcher studying GIP/GLP-1 receptor pharmacology, metabolic biology, or dual incretin agonist mechanisms, this guide is for you. If you are looking for a prescription medication, you need to speak to a licensed prescriber — not a research chemical supplier.
Key Takeaways
- Mounjaro is a branded Prescription Only Medicine (POM): Mounjaro is Eli Lilly’s brand name for tirzepatide — a dual GIP/GLP-1 receptor agonist licensed and available only by prescription in the UK under the Human Medicines Regulations 2012. Pure Grade Labs does not sell Mounjaro.
- Research-grade tirzepatide is a distinct supply category: Tirzepatide can be legally supplied as a research chemical for laboratory research, in vitro experimentation, and preclinical scientific study — under a different regulatory pathway to the one governing prescription medicines. Pure Grade Labs operates within this research chemical framework.
- Same active molecule, different regulatory context: The tirzepatide molecule is the same in both Mounjaro and research-grade tirzepatide — a dual GIP and GLP-1 receptor agonist with CAS number 2023788-19-2. The difference is not the compound; it is the regulatory pathway, the intended use, and the supply framework.
- SURMOUNT-1 trial data: In the Phase III SURMOUNT-1 trial, participants receiving tirzepatide 15mg once weekly demonstrated a mean body weight reduction of approximately 20.9% over 72 weeks — the most significant published weight reduction data for any GLP-1 class compound at the time of publication (2022).
- 99%+ HPLC-verified purity: Pure Grade Labs supplies tirzepatide 10mg verified to ≥99% purity by HPLC with a batch-specific COA. Prescription-only medicine in many jurisdictions. For research purposes only. Not for human consumption.
Research-Grade Tirzepatide — UK Supply
Tirzepatide 10mg available for laboratory research. 99%+ HPLC-verified purity. Batch-specific COA included with every order.
Prescription-only medicine in many jurisdictions. For research purposes only. Not for human consumption.
Can You Buy Mounjaro in the UK Without a Prescription?
No. Mounjaro is a Prescription Only Medicine (POM) in the UK under the Human Medicines Regulations 2012. This means it can only be legally supplied with a valid prescription issued by a licensed medical prescriber — a GP, private clinician, or other appropriately qualified healthcare professional. Mounjaro is approved by the MHRA for use in adults with type 2 diabetes mellitus as an adjunct to diet and exercise, and has subsequently been approved for chronic weight management under the brand name Zepbound in certain jurisdictions.
Pure Grade Labs does not sell Mounjaro. We are a research chemical supplier. We sell research-grade tirzepatide — the same active molecule — but for laboratory research purposes only, under the research chemical supply framework. This is a meaningful legal and practical distinction, and this guide explains it clearly because the distinction matters both for researchers and for anyone searching to buy Mounjaro who needs to understand what options actually exist and what is and is not legal.
Anyone offering to sell Mounjaro branded product without a prescription in the UK, or from unlicensed sources, is operating illegally under UK medicines law. This applies to online marketplaces, grey-market importers, and any supplier who claims to sell Mounjaro outside the licensed prescribing pathway. Both researchers and consumers should be aware of this risk when searching for this compound.
What Is Mounjaro? What Is Tirzepatide?
Mounjaro is a brand name. The active molecule inside Mounjaro is tirzepatide — a synthetic 39-amino acid peptide developed by Eli Lilly and approved by the FDA in May 2022 for type 2 diabetes management. Tirzepatide is a first-in-class “twincretin” — a dual agonist that activates both the GLP-1 (glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. This dual mechanism distinguishes tirzepatide from earlier GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), which target GLP-1 receptors only.
CAS number: 2023788-19-2. Molecular weight: approximately 4,813.5 Da. Eli Lilly markets tirzepatide as Mounjaro for type 2 diabetes management and as Zepbound (in the USA) for chronic weight management at higher doses. The active molecule is identical across both branded presentations — tirzepatide, a GIP/GLP-1 dual receptor agonist.
The Dual Incretin Mechanism
Tirzepatide’s research interest derives substantially from its dual incretin mechanism. GLP-1 receptor agonism drives insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite — a mechanism shared with semaglutide. GIP receptor agonism adds a complementary dimension: GIP is an incretin hormone that potentiates insulin secretion (similar to GLP-1) but also affects adipose tissue directly, modulating fat storage and lipolysis through GIPR signalling in adipocytes.
The combination of GLP-1R and GIPR agonism in a single molecule is what generated the clinical outcomes data that made tirzepatide’s trial results among the most significant in metabolic medicine research in the past decade. The SURMOUNT-1 and SURPASS trial programmes provided the clinical evidence for this dual mechanism’s metabolic effects at scale — and those published trial data are the primary research basis for tirzepatide’s interest as a laboratory research compound.
When the SURMOUNT-1 Phase III results were published in the New England Journal of Medicine in 2022, the tirzepatide 15mg group’s mean weight reduction of 20.9% at 72 weeks represented a result that exceeded what had previously been achievable with any approved pharmacological intervention for weight management. For metabolic biology researchers, the publication created immediate demand for research-grade tirzepatide to study the dual GIP/GLP-1 mechanism in preclinical and in vitro models — separating the contributions of each receptor axis to the overall metabolic phenotype.
Tirzepatide Research: What the Clinical Trials Show
The tirzepatide clinical trial programme is among the most extensive for any dual incretin agent. The SURPASS programme (SURPASS-1 through SURPASS-6) evaluated tirzepatide across different type 2 diabetes patient populations; the SURMOUNT programme (SURMOUNT-1 through SURMOUNT-4) evaluated tirzepatide for chronic weight management.
SURMOUNT-1: Weight Management Data
SURMOUNT-1 (Jastreboff AM et al., NEJM 2022) randomised 2,539 adults with BMI ≥30 kg/m² (or ≥27 kg/m² with weight-related comorbidities) to tirzepatide 5mg, 10mg, 15mg, or placebo weekly for 72 weeks. At the primary endpoint:
- Tirzepatide 5mg: mean weight reduction of 15.0% from baseline
- Tirzepatide 10mg: mean weight reduction of 19.5% from baseline
- Tirzepatide 15mg: mean weight reduction of 20.9% from baseline
- Placebo: mean weight reduction of 3.1% from baseline
These results — particularly the 20.9% reduction in the highest-dose group — represented the largest weight reduction observed in any randomised controlled trial of an approved pharmacological agent at the time of publication. The magnitude of effect generated substantial research interest in the dual GIP/GLP-1 mechanism as a model for future metabolic drug development.
SURPASS Programme: Glycaemic Data
The SURPASS trials evaluated tirzepatide for HbA1c reduction in type 2 diabetes populations. Key findings from the SURPASS programme:
- SURPASS-1 (monotherapy): HbA1c reductions of 1.87–2.07% at 40 weeks across dose groups
- SURPASS-2 (vs. semaglutide 1mg): Tirzepatide 15mg produced HbA1c reduction of 2.3% vs. 1.9% for semaglutide — statistically significant superiority
- SURPASS-3 (vs. insulin degludec): Tirzepatide produced greater HbA1c reduction with lower hypoglycaemia incidence
The SURPASS-2 head-to-head comparison with semaglutide is particularly significant for metabolic biology research: it provided direct evidence that the dual GIP/GLP-1 mechanism produces greater glycaemic control than GLP-1 agonism alone at therapeutic doses — confirming the mechanistic hypothesis that GIPR co-agonism adds metabolic benefit beyond GLP-1R activation.
Research-Grade Tirzepatide — For Laboratory Research
Tirzepatide 10mg. 99%+ HPLC-verified. Batch COA. UK supply. Also available: Semaglutide 10mg and Metabolic Research Stack.
Prescription-only medicine in many jurisdictions. For research purposes only. Not for human consumption.
What Is Research-Grade Tirzepatide?
Research-grade tirzepatide is the tirzepatide molecule — CAS 2023788-19-2, the same dual GIP/GLP-1 receptor agonist peptide as the active molecule in Mounjaro — supplied as a research chemical for laboratory research purposes under the research chemical supply framework, rather than as a pharmaceutical product under the medicines regulatory framework.
The distinction between research-grade tirzepatide and Mounjaro (branded tirzepatide) is not the molecule itself. The distinction is the regulatory pathway, the intended use, and the supply framework. Mounjaro is a finished pharmaceutical product: formulated at precise concentrations in a prefilled autoinjector, manufactured to pharmaceutical GMP standards, approved for specific clinical indications, available only via prescription from licensed prescribers. Research-grade tirzepatide is a lyophilised powder: verified by HPLC to purity standard, supplied with a batch-specific COA, intended for laboratory research, and sold under the research chemical framework. It is not for human consumption.
Pure Grade Labs supplies tirzepatide 10mg as a lyophilised powder, verified to ≥99% purity by HPLC, with a batch-specific COA documenting purity, batch number, test date, and analytical method. This is the standard researchers in GIP/GLP-1 receptor pharmacology, metabolic biology, and incretin mechanism research require.
Mounjaro vs. Ozempic: Mechanism Comparison
| Dimension | Mounjaro (Tirzepatide) | Ozempic (Semaglutide) |
|---|---|---|
| Manufacturer | Eli Lilly | Novo Nordisk |
| Receptor mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist only |
| Sequence length | 39 amino acids | 31 amino acids |
| CAS number | 2023788-19-2 | 910463-68-2 |
| FDA approval (diabetes) | May 2022 | December 2017 |
| SURPASS-2 head-to-head (15mg vs. sema 1mg) | HbA1c −2.3% (superior) | HbA1c −1.9% (active comparator) |
| Research-grade supply (PGL) | Tirzepatide 10mg | Semaglutide 10mg |
UK Legal Framework: Mounjaro, Tirzepatide, and Research Chemical Supply
Mounjaro (tirzepatide) is a Prescription Only Medicine under the Human Medicines Regulations 2012 in the UK, approved by the MHRA for use in adults with type 2 diabetes mellitus. As a POM, it is available through NHS prescribing (where clinically indicated) and through licensed private prescribers. The branded product cannot be obtained legally without a valid prescription from a licensed prescriber.
The research chemical supply framework operates under different provisions: research chemicals — compounds supplied strictly for laboratory research and not for human consumption — are supplied outside the medicines regulatory framework when positioned correctly and when compliance language is consistent and accurate. Pure Grade Labs supplies research-grade tirzepatide under this framework, with explicit compliance language across all product information: prescription-only medicine in many jurisdictions, for research purposes only, not for human consumption.
Researchers purchasing tirzepatide from Pure Grade Labs are responsible for compliance with all applicable regulations in their jurisdiction. The research chemical framework does not override prescription medicine regulations for human use — it provides a separate pathway for legitimate scientific research applications.
If You Need Mounjaro: Your Legitimate Options
If you are searching for Mounjaro as a patient or potential patient — not as a researcher — the correct routes are:
- NHS prescribing: Mounjaro is available on the NHS for eligible patients with type 2 diabetes — speak to your GP or diabetes specialist.
- Private prescribing: Licensed private prescribers (private GPs, weight management clinics with prescribing authority) can prescribe Mounjaro for eligible patients.
- Licensed online pharmacies: Some licensed UK online pharmacies supply Mounjaro where a valid online prescribing consultation and prescription has been completed. Ensure any pharmacy is MHRA-registered and GPhC-regulated.
Do not source Mounjaro from unlicensed suppliers, overseas grey-market sources, or research chemical suppliers. These sources operate outside the licensed medicines framework and provide no guarantee of product authenticity, safety, or appropriate clinical oversight.
Frequently Asked Questions
Can I buy Mounjaro without a prescription in the UK?
No. Mounjaro (tirzepatide) is a Prescription Only Medicine in the UK. It requires a valid prescription from a licensed prescriber. There is no legal route to obtain Mounjaro without a prescription — not from research chemical suppliers, not from online marketplaces, not from overseas grey-market sources. Pure Grade Labs does not sell Mounjaro.
What is research-grade tirzepatide and how does it differ from Mounjaro?
Research-grade tirzepatide is the same active molecule as the tirzepatide in Mounjaro (CAS: 2023788-19-2), but supplied as a lyophilised research chemical for laboratory research — not as a finished pharmaceutical product for human use. Mounjaro is formulated in prefilled autoinjectors at precise clinical doses, manufactured to pharmaceutical GMP standards, and available only via prescription. Research-grade tirzepatide is a powder for laboratory research use, verified by HPLC, with a batch-specific COA, and supplied under the research chemical framework. It is not for human consumption.
What does tirzepatide’s dual mechanism mean in research terms?
Tirzepatide is a dual agonist at both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors — the first approved drug of this class. In research terms, this dual mechanism allows investigation of the additive or synergistic effects of combined GIP/GLP-1 receptor activation on insulin secretion, glucagon suppression, gastric emptying, adipose tissue signalling, and appetite regulation — compared to GLP-1 agonism alone (semaglutide). The published SURPASS trial data confirming tirzepatide’s superiority over semaglutide in HbA1c reduction provides a clinical basis for this mechanistic research interest.
What purity standard does Pure Grade Labs maintain for tirzepatide?
Pure Grade Labs supplies research-grade tirzepatide 10mg verified to ≥99% purity by HPLC. A batch-specific COA — including purity data, batch number, test date, analytical method, and laboratory details — is included with every order.
Is tirzepatide available on the NHS?
Mounjaro (tirzepatide) is available on the NHS for eligible patients with type 2 diabetes in whom it is indicated and where prescribing criteria are met. Eligibility and prescribing decisions are made by qualified healthcare professionals. Pure Grade Labs has no role in prescribing decisions and does not supply Mounjaro — only research-grade tirzepatide for laboratory research purposes.
Tirzepatide 10mg — Research Chemical Supply
HPLC ≥99% purity. Batch COA. UK supply. For laboratory research purposes only.
Prescription-only medicine in many jurisdictions. Not for human consumption.
Summary
Mounjaro (tirzepatide) is a Prescription Only Medicine in the UK — available only via a licensed prescriber, not from research chemical suppliers. Pure Grade Labs does not sell Mounjaro. The branded Eli Lilly pharmaceutical product requires a valid prescription and is available through NHS and licensed private prescribing pathways.
What Pure Grade Labs supplies is research-grade tirzepatide 10mg — the same active molecule (CAS: 2023788-19-2), supplied as a lyophilised research chemical for in vitro and preclinical laboratory research under the research chemical supply framework. With ≥99% HPLC-verified purity, batch-specific COA, and UK supply, it provides researchers studying dual GIP/GLP-1 receptor mechanisms, incretin biology, and metabolic signalling with access to a well-characterised compound supported by one of the most substantial clinical trial programmes in recent metabolic medicine research history.
Researchers working across the GLP-1 agonist landscape may also wish to explore research-grade semaglutide 10mg — the GLP-1-only comparator compound — or the Metabolic Research Stack.
References
- Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 387:205-216. DOI: 10.1056/NEJMoa2206038
- Frías JP et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 385:503-515. DOI: 10.1056/NEJMoa2107519 (SURPASS-2)
- Rosenstock J et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 398(10295):143-155. DOI: 10.1016/S0140-6736(21)01324-6
- Eli Lilly and Company. (2022). Mounjaro (tirzepatide) EU Summary of Product Characteristics. EMA.
- Human Medicines Regulations 2012. SI 2012/1916. UK Statutory Instruments. legislation.gov.uk